Yifei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yifei Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Juan Tao
Department of Dermatology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST) Wuhan China
3 shared publications - Changzheng Huang
Department of Dermatology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
1 shared publication Chen Shen
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
1 shared publication- Chen Shen
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China
1 shared publication Danping Liu
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
1 shared publication- Enzhu Dong
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China
1 shared publication
Latest Publications
- 15 January 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1918-1929.e11
Myeloid-driven inflammation highlights ADGRE2 as a biomarker in prurigo nodularis: Integrated multiomics analysis
- 15 January 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1918-1929.e11
Myeloid-driven inflammation highlights ADGRE2 as a biomarker in prurigo nodularis: Integrated multiomics analysis
- Open Access
- 6 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study
Background: The risk of venous thromboembolism (VTE) among patients with atopic dermatitis (AD), especially when receiving treatment with Janus kinase inhibitors (JAKi), has been reported in observational studies. however, the causal relationships between them remain unclear. We aim to explore the causal effects of AD and JAKi on VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Methods: Two-sample Mendelian randomization (MR) analyses were conducted to examine the causal between genetic susceptibility to AD or JAKi target genes (including JAK1, JAK2, JAK3 and tyrosine kinase 2 [TYK2]) and VTE (encompassing DVT and PE) using summary statistics from genome-wide association studies and eQTLGen project. Inverse variance weighting with random effect method was used as the main analytic approach. Pleiotropy and heterogeneity tests were conducted to assess the robustness of the findings. Results: No significant causal effects were found between AD and the risk of (odds ratio [OR]: 0.97, 95% confidence interval [CI]: 0.91-1.03, P = .352), DVT (OR: 0.99, 95% CI: 0.89-1.10, P = .789), and PE (OR: 1.06, 95% CI: 0.93-1.20, P = .387). Similarly, there was no causal association between the expression of JAK1, JAK2, JAK3 or TYK2 and VTE, DVT and PE. Conclusion: The MR analysis revealed no genetic causal relationships between either AD or JAKi target genes and VTE. These findings may provide a reference for clinicians in prescribing JAKi for patients with AD.
- 6 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Open AccessAssociation of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study
Background: The risk of venous thromboembolism (VTE) among patients with atopic dermatitis (AD), especially when receiving treatment with Janus kinase inhibitors (JAKi), has been reported in observational studies. however, the causal relationships between them remain unclear. We aim to explore the causal effects of AD and JAKi on VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Methods: Two-sample Mendelian randomization (MR) analyses were conducted to examine the causal between genetic susceptibility to AD or JAKi target genes (including JAK1, JAK2, JAK3 and tyrosine kinase 2 [TYK2]) and VTE (encompassing DVT and PE) using summary statistics from genome-wide association studies and eQTLGen project. Inverse variance weighting with random effect method was used as the main analytic approach. Pleiotropy and heterogeneity tests were conducted to assess the robustness of the findings. Results: No significant causal effects were found between AD and the risk of (odds ratio [OR]: 0.97, 95% confidence interval [CI]: 0.91-1.03, P = .352), DVT (OR: 0.99, 95% CI: 0.89-1.10, P = .789), and PE (OR: 1.06, 95% CI: 0.93-1.20, P = .387). Similarly, there was no causal association between the expression of JAK1, JAK2, JAK3 or TYK2 and VTE, DVT and PE. Conclusion: The MR analysis revealed no genetic causal relationships between either AD or JAKi target genes and VTE. These findings may provide a reference for clinicians in prescribing JAKi for patients with AD.
- Open Access
- 1 January 2023
- Published by Wiley in Dermatologic Therapy
- Vol. 2023 (1)
Dupilumab Improves Clinical Scores in Pediatric Patients Aged 2 to <18 Years with Uncontrolled Atopic Dermatitis: A Single‐Center, Real‐World Study
Dupilumab is the first biologic agent approved for treatment of moderate to severe atopic dermatitis (AD). Phase 3 clinical trials have shown the efficacy and safety in AD children. However, real‐world evidence is still scarce. Thirty‐nine pediatric patients with uncontrolled AD who regularly received dupilumab were included in a single‐center retrospective study. Eight patients (20.5%) were aged 2 to <6 years, fifteen (38.5%) were 6 to <12 years, and sixteen were 12 to <18 years. Changes in clinical AD scores (EASI, SCORAD, P‐NRS, CDLQI, and POEM) at baseline, week 4 (W4), W10, and W16, as well as safety data were collected. At W16, the average EASI values dropped from 29.0 ± 16.2 to 5.1 ± 4.7, and 22 patients (73.3%) achieved 75% improvement in EASI. 16 patients (53.3%) achieved 75% improvement in SCORAD. Significant reduction was also observed in the changes of P‐NRS, CDLQI, and POEM values. Notably, the change of clinical scores was similar among three age subgroups. At W16, the mean percent decreases in EASI for 2 to <6 years, 6 to <12 years, and 12 to 6‐year‐old patients and the injection site reaction in one <6‐year‐old child. Dupilumab exhibited favorable efficacy and safety profile, including the 2 to <6 years old subgroup.
- 1 January 2023
- Published by Wiley in Dermatologic Therapy
- Vol. 2023 (1)
Open AccessDupilumab Improves Clinical Scores in Pediatric Patients Aged 2 to <18 Years with Uncontrolled Atopic Dermatitis: A Single‐Center, Real‐World Study
Dupilumab is the first biologic agent approved for treatment of moderate to severe atopic dermatitis (AD). Phase 3 clinical trials have shown the efficacy and safety in AD children. However, real‐world evidence is still scarce. Thirty‐nine pediatric patients with uncontrolled AD who regularly received dupilumab were included in a single‐center retrospective study. Eight patients (20.5%) were aged 2 to <6 years, fifteen (38.5%) were 6 to <12 years, and sixteen were 12 to <18 years. Changes in clinical AD scores (EASI, SCORAD, P‐NRS, CDLQI, and POEM) at baseline, week 4 (W4), W10, and W16, as well as safety data were collected. At W16, the average EASI values dropped from 29.0 ± 16.2 to 5.1 ± 4.7, and 22 patients (73.3%) achieved 75% improvement in EASI. 16 patients (53.3%) achieved 75% improvement in SCORAD. Significant reduction was also observed in the changes of P‐NRS, CDLQI, and POEM values. Notably, the change of clinical scores was similar among three age subgroups. At W16, the mean percent decreases in EASI for 2 to <6 years, 6 to <12 years, and 12 to 6‐year‐old patients and the injection site reaction in one <6‐year‐old child. Dupilumab exhibited favorable efficacy and safety profile, including the 2 to <6 years old subgroup.
- 29 December 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (5) , E166-E167
Nailfold capillary abnormalities: A predictor of psoriatic arthritis?
- 29 December 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (5) , E166-E167
Nailfold capillary abnormalities: A predictor of psoriatic arthritis?